Alzheimer’s breakthrough research from Eli Lilly gives ‘real hope’ to millions of patients and their families
https://www.siliconvalley.com/2023/05/04/alzheimers-breakthrough-research-from-eli-lilly-gives-real-hope-to-millions-of-patients-and-their-families/
Eli Lilly has announced that its Alzheimer’s treatment drug has slowed cognitive decline and functional decline in a study, giving millions of patients and their families “real hope that they will have a brighter future fighting this disease.”
The pharmaceutical company on Wednesday shared the results from its TRAILBLAZER-ALZ2 Phase 3 clinical trial of donanemab for the treatment of early symptomatic Alzheimer’s disease.